Search clinical trials for: SGN-CD19A

Total 1419 results

University Health Network, Toronto
Weston Brain Institute

Recruiting

Subgenual Cingulate Deep Brain STIMulation for Apathetic Behavioral Variant FRONtotemporal Dementia (FRONSTIM)

Frontotemporal Dementia | Deep Brain Stimulation

Canada
Lenus Therapeutics, LLC

Terminated

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Dystrophic Epidermolysis Bullosa | Junctional Epidermolysis Bullosa

United States
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States
The Cleveland Clinic

Recruiting

Continuous Ward Monitoring With the GE Portrait Mobile Monitoring Solution: the COSMOS Trial (COSMOS)

Postoperative Complications

United States
National Cancer Institute (NCI)

Suspended

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); OnLume Inc.

Recruiting

ICG and SLN Mapping

Breast Cancer

United States
University Hospital, Ghent
University Ghent

Recruiting

Effect of Infant Sign Training on Speech-language Development

Cleft Palate Children

Belgium
Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
Zhejiang University

Recruiting

A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China (HERITAGE)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Cognitive Impairment | Alzheimer Disease | Mental Disorder | Cognition Disorder | Vascular Cognitive Impairment | Dement

China
Centre Hospitalier Universitaire de la Réunion

Not yet recruiting

Sun Exposure for Outdoor Athletes in Mayotte and Reunion Island (EXSPOSOL)

Sun Exposure

Mayotte, Réunion
University of Southern Denmark
Odense University Hospital; Danish Cancer Society

Active, not recruiting

Sentinel Node Mapping in Women With Endometrial and Cervical Cancer (SENTIREC II)

Uterine Cervical Neoplasms | Uterine Neoplasms

Denmark
Allergan

Withdrawn

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia (ARIES)

Presbyopia

United States
Institut National de la Santé Et de la Recherche...

Active, not recruiting

Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts (EBGraft)

Epidermolysis Bullosa Dystrophica, Recessive

France
Riphah International University

Completed

Qui Gong Programme vs Short Form Sun Style Tai Chi in COPD Patients

COPD

Pakistan
University Hospital, Basel, Switzerland
Clinical Trial Unit, University Hospital Basel, Switzerland

Completed

Camera-based Measurement of Respiratory Rates

Tachypnea

Switzerland
University of California, San Francisco
Orthopaedic Trauma Association; Muhimbili Orthopaedic Institute; Orthopaedic...

Completed

Nails Versus Plates for Femur Fractures in Dar es Salaam, Tanzania

Femoral Fractures

Tanzania
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Seagen Inc.

Completed

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

United States, Canada
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Shanghai Jiao Tong University School of Medicine
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

China
Goztepe Training and Research Hospital

Recruiting

A New Method for Deltoid Ruptures: Gap Sign

Ankle Fractures | Ligament Rupture | Ligament Injury

Turkey
siRNAgen Therapeutics Inc.

Active, not recruiting

The First-in-human Study of SRN-001 in Healthy Participants

Idiopathic Pulmonary Fibrosis

Australia
AbbVie

Terminated

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Presbyopia

United States
Dana-Farber Cancer Institute
Harvard Medical School (HMS and HSDM); Brigham and Women's Hospital; University... and other collaborators

Completed

Skin Cancer Screening and Education at Beaches (SHADE)

Skin Cancer

United States
RegeneRx Biopharmaceuticals, Inc.
sigma-tau i.f.r. S.p.A.

Completed

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers (SSVS)

Venous Stasis Ulcers

Italy, Poland
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
University of Washington
National Cancer Institute (NCI); Seagen Inc.

Active, not recruiting

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin Lymphoma

United States
Columbia University

Completed

The READ-SG Study: Effect of Peer-Facilitated Small Group Discussions (READ-SG)

Burnout, Professional | Emotional Intelligence | Peer Influence

United States
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Seagen Inc.

Recruiting

A Study of SGN-B6A in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Non-Small Cell Lung | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | HER2 Negative Breast Neoplasms and other conditions

United States, Spain, United Kingdom, France, Switzerland
Seoul National University Hospital

Recruiting

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Very High Risk Acute Lymphoblastic Leukemia | CD19 CAR-T Therapy

Korea, Republic of
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Recruiting

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
Hebei Senlang Biotechnology Inc., Ltd.
Tongji Hospital

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors

China
Mitchell Cairo

Recruiting

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Hodgkin Lymphoma | Sickle Cell Disease | Acute Leukemia | Beta-Thalassemia | Non-hodgkin Lymphoma | Severe Aplastic Anemia | Diamond Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann

United States
University College, London

Enrolling by invitation

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Cellular Biomedicine Group Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Terminated

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Lymphoma

United States
Sonnet BioTherapeutics
Hoffmann-La Roche

Recruiting

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Advanced Solid Tumor | Platinum-resistant Ovarian Cancer

United States, Australia

Search clinical trials for: SGN-CD19A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations